Brain Energy Metabolism - Vocabulary Flashcards (Video Notes)

Lipid droplets and lipase inhibition in neurons: key findings

• The study shows lipid droplets (LDs) in synaptic terminals and their association with mitochondria in neurons; LDs colocalize with synaptic terminals and mitochondrial markers under certain conditions.
• Two experimental approaches yielded LD–synapse correlations: immunohistochemistry and overexpression of a reporter. In both, LDs appeared to correlate with DDHD2 (a brain lipase) signals and synaptic terminals.
• Correlation between DDHD2 and synaptic terminals reported as around $r \,\approx\, 0.6$, indicating a notable but not exclusive relationship.
• A key concern raised in class: the figures were not clearly labeled for treatment condition; some panels seemed to show untreated samples, while others implied antagonist (lipase inhibitor) treatment. The point of the figures was to show LDs and lipid metabolism in treated vs untreated samples, but the exact treatment status of each panel was occasionally unclear.
• The lipase inhibitor used is etomoxir, which blocks the transport of fatty acids into mitochondria by inhibiting CPT1, leading to lipid droplet accumulation when lipolysis or fatty acid entry is blocked.
• In the schematic, LDs accumulate when lipase activity is blocked and LDs are not efficiently mobilized into mitochondria for oxidation; empirical data show LDs near synaptic vesicles and mitochondria.
• Experimental setup included manipulation of lipid metabolism and energy substrates to explore whether neurons can use LD-derived lipids to support energy needs at synapses.
• LDs were observed in two distinct contexts: (1) blockade of lipase activity alone, leading to LD buildup; (2) blockade of lipid import into mitochondria or suppression of neuronal activity, influencing LD distribution and trafficking.
• In some panels, mitochondria were labeled blue, LDs pink/red, and synaptic markers green; the overlay technique produced yellow where green and red overlapped, indicating colocalization.
• The researchers also explored LD–mitochondria interactions by adding a mitochondrial marker to certain panels (panel f), noting colocalization of LDs, mitochondria, and synaptic terminals.
• A broader point: brain mitochondria are heterogeneous and specialized by subcellular location, which may influence LD interactions with energy metabolism at synapses.
• The authors discuss APOE (Apolipoprotein E) in the context of brain lipid metabolism; APOE is known to be a brain lipid-handling protein with isoforms (notably APOE4) linked to Alzheimer's disease risk. The transcript highlights a possible brain-specific lipase role and notes that lipid droplets accumulate in Alzheimer's disease, suggesting energy failure and lipid dysregulation may contribute to pathology.
• The paper includes in vivo experiments in mice and in vitro experiments in rat neuron cultures, raising questions about cross-species modeling (rats vs. mice) and translational relevance to torpor or hibernation physiology.
• The overall translational relevance emphasized: energy metabolism in neurons, lipid handling, and LD dynamics may be connected to neurodegenerative disease, especially where energy failure is implicated (e.g., Alzheimer's disease).
• Discussion questions raised by the presenter included broader connections, critical evaluation, and future directions, as well as the potential clinical relevance of lipid droplet dynamics in neurons.

Experimental setup and data interpretation (Nature Metabolism paper summary)

• Two main approaches were used to visualize LDs and lipid handling in neurons:
  • Immunohistochemistry (IHC)
  • Reporter-based overexpression to visualize lipid/LD markers
• Observed overlap and colorimetric correlation in LDs with synaptic terminals when LDs were co-labeled with synaptic markers.
• LD–synapse correlations calculated as roughly $r\approx 0.6$ in the two experiments, supporting a relationship between DDHD2-mediated lipolysis and synaptic terminals.
• In one set of figures, panels were described as “not treated” with lipase inhibitors, while the other set involved inhibition of lipase with etomoxir and/or inhibition of fatty acid transport into mitochondria; the exact treatment labels on each panel were not always explicit in the captions.
• LD accumulation observed when lipase activity is inhibited or when fatty acid entry into mitochondria is blocked, producing robust LD formation near synapses.
• The authors then combined LD visualization with mitochondrial markers to show three-way colocalization of LDs, mitochondria, and synaptic terminals under certain conditions.
• Quantitative data indicated that a substantial proportion (~70%) of LDs were near synaptic structures in some conditions, suggesting functional coupling between lipid stores and synaptic energy demands.
• The figure discussion highlighted that LDs and organelles could be physically associated in synaptic terminals, implying local lipid metabolism may support presynaptic or postsynaptic activity.
• The study also discusses the involvement of various transport inhibitors and metabolic blockers to dissect the source and destination of lipid-derived energy:
  • Etomoxir to block mitochondrial fatty acid entry (CPT1 inhibitor)
  • Blockade of fatty acid transport into mitochondria to assess trafficking of fatty acids from LDs to mitochondria
  • In some experiments, inhibitors of action potential or transport into mitochondria modulated LD formation and LD utilization.
• ATP measurements were used to gauge functional consequences of lipid metabolism on neuronal energy status by using an ATP sensor in terminals; stimulating neurons and blocking lipid transport into mitochondria caused ATP to drop under stimulation, suggesting mitochondrial oxidation of LD-derived lipids supports ATP during activity.
• The experiments used two conditions for fuel availability:
  • With palmitic acid as a lipid fuel, measuring the capacity for synaptic vesicle turnover and ATP maintenance
  • With glucose as fuel, showing that the presence of glucose can rescue or alter the dependence on lipid-derived energy
• In vivo experiments involved five hours of food restriction, followed by injections of lipase inhibitor or mitochondrial transporter blocker, and measurement of core body temperature; the presenter notes potential toxicity concerns and questions about whether such systemic treatments specifically impact brain energy metabolism rather than general physiology.
• The presenter notes that some agents used (e.g., KLH45) might be used to induce lipid accumulation, while etomoxir/metabolic inhibitors are employed to dissect lipid utilization pathways; there are interpretive uncertainties about these treatments in certain panels.
• Overall, the in vivo and in vitro data converge on a model where lipid-derived energy contributes to synaptic endurance and sustained activity, with LDs acting as a local lipid reservoir that can be mobilized when mitochondrial fatty acid oxidation is permitted.

Mechanistic interpretation and key concepts

• Lipid droplets in neurons can be dynamically regulated by lipases such as DDHD2 and by transport into mitochondria for beta-oxidation; blocking lipolysis or mitochondrial entry leads to LD accumulation and altered energy dynamics.
• Etomoxir inhibits CPT1, blocking transport of long-chain fatty acids into mitochondria; this leads to lipid droplet accumulation due to impaired β-oxidation and lipid utilization.
• LDs can be physically associated with synaptic terminals and mitochondria, indicating a potential local energy reserve to sustain synaptic activity during periods of high demand.
• Mitochondrial heterogeneity and compartmentalization influence how LDs are used at different subcellular locales; synaptic mitochondria may have specialized metabolic roles.
• The role of APOE in brain lipid metabolism may connect lipid droplet dynamics to neurodegenerative vulnerability (APOE4 association with Alzheimer’s disease risk).
• In vivo experiments suggest that disrupting lipid utilization can affect core body temperature under fasting or energy-restricted conditions, pointing to systemic energy balance effects, but the direct brain-specific implications require careful interpretation.
• Important caveat: some drugs used (e.g., KLH45, methyl/cyclo inhibitors) may have non-specific or toxic effects; conclusions should consider potential off-target actions and overall organismal energy balance.

Core brain energy metabolism concepts (review content from the course slides)

• Primary pathways for energy in the brain:
  • Glycolysis (with and without oxygen): anaerobic glycolysis yields lactate; aerobic glycolysis feeds into the mitochondria via pyruvate.
  • Fatty acid oxidation (beta-oxidation) and its contribution to acetyl-CoA production for the TCA cycle.
  • TCA cycle (Krebs cycle) and the citric acid cycle in neurons; generation of NADH and FADH2 for oxidative phosphorylation.
  • Electron transport chain (ETC) and oxidative phosphorylation: conversion of NADH/FADH2 energy into ATP.
  • Anaerobic glycolysis produces ATP without oxygen but is less efficient and often context-dependent in the brain.
• Brain fuels and transporters:
  • Glucose is the primary brain fuel; brain glucose uptake is measured by PET using FDG; cerebral blood flow is tightly coupled to metabolism (neurovascular coupling).
  • Ketone bodies (acetoacetate, β-hydroxybutyrate, acetone) can fuel the brain, especially during fasting or ketogenic diet; they cross the blood–brain barrier via monocarboxylate transporters (MCTs) and are converted to acetyl-CoA in neurons/astrocytes entering the TCA cycle.
  • Fatty acids generally do not cross the BBB in large amounts; most brain lipid needs are met from in situ synthesis or transport of ketones and other metabolites.
  • Lactate as a brain fuel is debated; lactate can be produced by astrocytes and shuttled to neurons; a lactate shuttle model has competing viewpoints and evidence.
• Key transporters and shuttles:
  • Carnitine palmitoyltransferase system (CPT1/CPT2) for transporting long-chain fatty acids into mitochondria; inhibited by etomoxir.
  • Monocarboxylate transporters (MCT1/2/4) for lactate and ketone bodies.
  • The malate–aspartate shuttle: transfers reducing equivalents (NADH) from cytosol to mitochondria via malate ↔ oxaloacetate and transamination with aspartate/glutamate; considered a major cytosol-to-mitochondria redox shuttle in many tissues.
  • The pyruvate dehydrogenase complex (PDH) and the pyruvate carboxylase (PC) routes that connect glycolysis to the TCA cycle; PDH converts pyruvate to acetyl-CoA, releasing CO₂ and generating NADH; PC carboxylates pyruvate to oxaloacetate for anaplerosis.
  • Glutamate–glutamine and GABA–glutamine shuttles: astrocytes take up glutamate, convert to glutamine (glutamine synthetase), export to neurons; neurons convert glutamine back to glutamate (glutaminase), or to GABA via decarboxylation; these shuttles help maintain neurotransmitter pools and metabolic balance.
• Key metabolic pathways and enzymes:
  • Glycolysis yields ATP; oxidative phosphorylation yields more ATP per glucose molecule.
  • Pyruvate dehydrogenase (PDH) converts pyruvate to acetyl-CoA; pyruvate carboxylase (PC) adds CO₂ to pyruvate to form oxaloacetate for anaplerosis.
  • Ketogenesis in the liver can generate ketone bodies, which are transported to brain and converted to acetyl-CoA for entry into the TCA cycle; ketogenic diet can be therapeutic in epilepsy and some disorders.
  • Transamination reactions move amino groups (e.g., converting oxaloacetate to aspartate via transamination with glutamate) and are central to amino acid metabolism and neurotransmitter balance.
• Energy balance, imaging, and brain activity:
  • Blood flow in the brain is autoregulated, driven by metabolic demand; neurovascular coupling links neuronal activity to local blood flow via metabolites such as adenosine, CO2, pH, and nitric oxide.
  • Imaging modalities reflect metabolism: PET with FDG measures glucose uptake; fMRI BOLD reflects hemodynamic responses to activity; MRS (1H, 13C) tracks metabolite levels and isotopomer labeling to follow metabolic pathways in vivo.
  • CMRO2 and CMRglc quantify oxygen and glucose consumption; the respiratory quotient (RQ) and oxygen-to-glucose utilization ratios reveal substrate usage and regional differences in energy metabolism.
• Brain energy and disease context:
  • Age-related changes reduce brain metabolism; Alzheimer's disease often shows reduced brain metabolism and altered lipid handling, possibly involving APOE isoforms and lipid droplets.
  • Lipid metabolism and energy supply become particularly relevant in neurodegenerative diseases where energy failure and lipid dysregulation may contribute to pathology.

The ketogenic pathway and ketone bodies (detailed)

• Ketone bodies produced in liver mitochondria from acetyl‑CoA via a pathway that yields acetoacetate, β-hydroxybutyrate, and acetone.
• Ketone bodies enter the brain via MCT transporters and are converted back to acetyl‑CoA to fuel the TCA cycle: $\text{Acetoacetate} \rightarrow \text{Acetoacetyl-CoA} \rightarrow 2 \; \text{acetyl‑CoA}$ (the acetyl‑CoA then enters the TCA cycle).
• Ketogenesis and ketolysis sustain brain energy during fasting, starvation, or ketogenic diet; this pathway is also explored as a therapeutic approach for some neurological conditions.

Glycolysis, PDH, and the pyruvate fate in neurons

• Aerobic glycolysis funnels pyruvate into the mitochondria via the PDH complex to form acetyl‑CoA. The PDH reaction: $\text{Pyruvate} + \text{CoA} + \mathrm{NAD}^+ \rightarrow \text{Acetyl‑CoA} + \mathrm{CO}_2 + \mathrm{NADH} + \mathrm{H}^+$
• Pyruvate can also be carboxylated by pyruvate carboxylase to oxaloacetate for anaplerosis: $\text{Pyruvate} + \mathrm{CO}<em>2 + \mathrm{ATP} \rightarrow \text{Oxaloacetate} + \mathrm{ADP} + \mathrm{P</em>i}$
• PDH regulation is a key control point linking glycolysis with the TCA cycle and energy production.
• In the absence of oxygen, glycolysis becomes anaerobic, producing lactate to regenerate NAD⁺ and sustain glycolytic flux: lactate formation from pyruvate via lactate dehydrogenase (LDH) is a reversible redox step.

The malate–aspartate shuttle (MAP) and other redox shuttles

• MAP is described as the most important pathway for transferring reducing equivalents from cytosolic NADH into the mitochondria in many tissues, including brain.
• Core steps (conceptual): cytosolic NADH reduces oxaloacetate to malate; malate crosses the mitochondrial membrane; malate is oxidized to oxaloacetate in the matrix, regenerating NADH inside mitochondria; oxaloacetate is transaminated to aspartate to exit to cytosol, where it is converted back to oxaloacetate. This shuttle enables NADH-derived electrons to reach the ETC without direct NADH transport across the inner mitochondrial membrane.
• Alternate shuttle: pyruvate–lactate shuttle can also interconvert pyruvate and lactate with LDH, contributing to cytosolic NAD+/NADH balance.
• Transamination reactions couple amino acid metabolism with energy production and maintain amino acid balance across compartments.
• Several mitochondrial carriers coordinate shuttling of intermediates (e.g., malate/α‑ketoglutarate carrier) to sustain shuttle cycles and metabolic flux.

The glutamate–glutamine and GABA shuttles

• Glutamate uptake and detoxification in astrocytes: astrocytes express glutamine synthetase to convert glutamate to glutamine, which is then released and taken up by neurons; neurons convert glutamine back to glutamate via glutaminase for neurotransmission.
• GABAergic neurons also rely on glutamine to supply glutamate that is subsequently decarboxylated to GABA; GABA can be converted back to glutamate and enter the TCA cycle or GABA shuttles.
• These shuttles help separate signaling roles of neurotransmitters from energy metabolism, enabling compartmentalized metabolism in neurons vs astrocytes.
• Enzymatic compartmentalization exists between cytosol and mitochondria, with neuron-specific and astrocyte-specific enzymes (e.g., phosphate-activated glutaminase in neurons, glutamine synthetase in astrocytes).

Mitochondrial specialization and cellular compartmentalization

• The brain shows mitochondrial heterogeneity by location and function; energy metabolism is compartmentalized within microdomains and organelles.
• Macromolecular complexes can organize enzymes in specific cellular locales to optimize flux through metabolic pathways.
• The idea of transporter-mediated shuttles (e.g., malate–aspartate shuttle) relies on coordinated carrier proteins that move metabolites across mitochondrial and plasma membranes.

Methods to study brain metabolism

• Isotopomer tracing using 13C-labeling and NMR: infers intracellular carbon flow through metabolic pathways; allows determination of where labeled carbon ends up (e.g., citrate, malate, pyruvate).
• Magnetic resonance spectroscopy (MRS) with 13C or 1H can monitor metabolic fluxes in vivo in humans and animals, though high-field magnets (7T, 11T) provide better resolution.
• Mass spectrometry can be used to trace isotopically labeled metabolites but lacks precise positional information compared to NMR.
• Positron emission tomography (PET) with fluorodeoxyglucose (FDG) measures glucose uptake; 15O-labeled tracers measure oxygen consumption (CMRO2).
• Two-deoxyglucose autoradiography historically linked to metabolic activity; modern PET uses labeled glucose analogs (FDG) to map metabolic activity in vivo.
• Fluorescence-based assays can visualize NAD(P)H and FAD signals in tissue sections, providing relative indicators of redox state and mitochondrial function.

Imaging and metabolic measurements in the brain

• fMRI BOLD: relies on hemodynamic responses to neural activity; reflects blood flow and oxygenation rather than direct neuronal activity.
• PET with FDG tracers: indicates glucose uptake and utilization across brain regions, useful for functional mapping and disease diagnostics.
• MRS (1H, 13C): tracks metabolite peaks such as N-acetylaspartate (NAA), glutamate/glutamine ( Glx ), GABA, and others; 13C MRS traces carbon flux through pathways using labeled substrates (e.g., glucose-13C).
• The balance of CMRO2 and CMRglc, plus the respiratory quotient (RQ), helps determine the predominant fuel source in a region and under different physiological states.
• The interaction of CO2, pH, adenosine, and other signaling molecules influences autoregulation of cerebral blood flow and is relevant for interpreting imaging data.

Fuel choices in the brain and their regulation

• Glucose is the primary brain fuel under normal conditions; glucose transporters (GLUTs) mediate uptake, and glycolytic flux feeds into the TCA cycle via PDH.
• Lactate as a neuronal fuel is debated; some models propose astrocyte-neuron lactate shuttling to sustain neurons during activity; others emphasize glycogen-derived lactate and glucose availability.
• Ketone bodies serve as alternative fuels during fasting or ketogenic diets; transported by MCTs and converted to acetyl‑CoA in mitochondria.
• Fatty acids generally do not directly cross the blood-brain barrier in significant amounts; LDs can act as lipid reservoirs within brain cells, particularly under conditions where lipolysis and transport into mitochondria are manipulated.

Context and translational relevance

• APOE is central to brain lipid metabolism and Alzheimer's disease risk; APOE4 is associated with altered lipid handling and may influence neuronal energy failure pathways.
• Lipid droplets in neurons and their interplay with synaptic function may provide insights into energy deficits in neurodegenerative diseases, where synaptic maintenance and energy availability are critical.
• The debate about lactate shuttles in the brain reflects a broader discussion on how brain cells coordinate energy supply and neurotransmitter cycling during activity.

Critical questions and future directions (from the session)

• Model choice and translational relevance: why use rat neuron cultures for in vitro studies and mice for in vivo work? Could models be streamlined to a single species for consistency?
• Safety and specificity of pharmacological interventions: many inhibitors/regulators used (e.g., lipase inhibitors, mitochondrial transport blockers) may have off-target or systemic effects; how to isolate brain-specific metabolic effects?
• The role of APOE and neuron-specific lipases in disease states: how do variations in APOE isoforms affect LD formation, lipid metabolism, and energy failure in neurons?
• How does lipid metabolism intersect with other energy pathways (glycolysis, ketogenesis, anaplerosis) during different physiological states (sleep, wakefulness, fasting, aging)?
• What are the implications for therapeutics: could targeting LD dynamics or neuronal lipid metabolism ameliorate energy deficits in neurodegenerative diseases?

Summary takeaways

• Neurons can form LDs within synaptic terminals, and LD dynamics appear linked to synaptic energy demands and mitochondria, particularly when lipolysis or lipid transport into mitochondria is perturbed.
• Inhibiting lipase activity or blocking mitochondrial entry of fatty acids drives LD accumulation and perturbs ATP homeostasis during neuronal stimulation, suggesting a functional role for lipid-derived energy in sustaining synaptic transmission.
• Brain energy metabolism is highly compartmentalized, with distinct shuttles, transporters, and organelle localization shaping how substrates like glucose, lactate, ketones, and lipids contribute to ATP production.
• Imaging and isotopic tracing provide complementary views of brain metabolism in vivo, enabling investigations into how energy metabolism relates to brain function, aging, and disease.
• The broader context links lipid metabolism, LDs, and energy failure to neurodegenerative diseases (e.g., Alzheimer’s) and highlights potential translational opportunities in targeting brain lipid pathways.

Appendix: key formulas and terms to memorize

• Pyruvate dehydrogenase reaction:
  $\text{Pyruvate} + \text{CoA} + \mathrm{NAD}^+ \rightarrow \text{Acetyl‑CoA} + \mathrm{CO}_2 + \mathrm{NADH} + \mathrm{H}^+$
• Pyruvate carboxylase reaction (anaplerosis):
  $\text{Pyruvate} + \mathrm{CO}<em>2 + \mathrm{ATP} \rightarrow \text{Oxaloacetate} + \mathrm{ADP} + \mathrm{P</em>i}$
• Ketogenesis (liver) overview (simplified):
  $2\, \text{Acetyl‑CoA} \rightarrow \text{Acetoacetyl‑CoA} \rightarrow \text{Acetoacetate} \rightarrow \text{β-hydroxybutyrate} \;(+\;\text{acetone})$
• Malate–aspartate shuttle (conceptual): cytosolic NADH reduces malate; malate enters mitochondria; malate oxidized to oxaloacetate, NADH produced; oxaloacetate transaminated to aspartate to shuttle back to cytosol.
• Glutamate–glutamine and GABA shuttles (conceptual): astrocytic conversion of glutamate to glutamine; neuronal uptake and reconversion to glutamate or GABA; involves compartmentalized enzymes (glutamine synthetase, glutaminase, glutamate decarboxylase).
• Imaging modalities (concepts): FDG-PET (glucose uptake), BOLD-fMRI (blood oxygenation level dependent), MRS (13C/1H NMR spectroscopy for metabolite tracking), CMRO2/CMRglc, respiratory quotient (RQ).